

**In the Supreme Court of the United States**

---

UNITED STATES OF AMERICA, CALIFORNIA, ILLINOIS, UTAH, AND WASHINGTON  
EX REL. TRACY SCHUTTE AND MICHAEL YARBERRY,  
*Petitioners,*

v.

SUPERVALU INC., AB ACQUISITION LLC, ACME MARKETS, INC., ALBERTSON'S, LLC,  
AMERICAN DRUG STORES, LLC, JEWEL FOOD STORES, INC., JEWEL OSCO SOUTHWEST  
LLC, NEW ALBERTSON'S, INC., SHAW'S SUPERMARKET, INC., STAR MARKET CO., INC.,  
FF ACQUISITIONS LLC, FOODARAMA LLC, SHOPPERS FOOD WAREHOUSE CORP.,  
SUPERVALU HOLDINGS, INC., AND SUPERVALU PHARMACIES, INC.,  
*Respondents.*

---

APPLICATION TO EXTEND TIME TO FILE PETITION FOR A WRIT OF  
CERTIORARI FROM MARCH 3, 2022 TO APRIL 1, 2022

---

To the Honorable Justice Barrett, as Circuit Justice for the Seventh Circuit:

Pursuant to 28 U.S.C. § 2101(c) and Supreme Court Rules 13.5, 22, and 30, petitioners Tracy Schutte and Michael Yarberry respectfully request that the time to file a petition for a writ of certiorari in this case be extended for 29 days to and including April 1, 2022. The United States Court of Appeals for the Seventh Circuit issued its opinion in this case on August 12, 2021 (App. A), and denied petitioners' timely petition for rehearing on December 3, 2021 (App. B). Absent an extension, the petition for a writ of certiorari would be due on March 3, 2022. Petitioners are filing this application more than ten days before that date. *See* Sup. Ct. R. 13.5. This Court has jurisdiction under 28 U.S.C. § 1254 to review this case.

## BACKGROUND

When the government reimburses pharmacies for drugs under Medicare Part D and Medicaid, it will not pay more than the “usual and customary” (U&C) price the pharmacy charges for drugs. In general, the U&C price is the lowest price the pharmacy charges to uninsured retail customers who pay out-of-pocket for drugs. Pharmacies are required to accurately report their U&C prices so that the government can reimburse appropriately.

Petitioners, as *qui tam* relators for the United States and several States, allege that respondents (collectively “SuperValu”) reported false data to the government in a scheme to inflate the amounts the government reimbursed for drugs. Thus, from 2006 until 2016, SuperValu matched competitor pharmacies’ prices for prescription drugs, and this policy resulted in SuperValu making the majority of its out-of-pocket sales for many drugs at discounted prices. But SuperValu did not report the discounted prices to the government, and so the government reimbursed SuperValu at higher rates than it should have. SuperValu executives knew that their discount program was problematic because it threatened the integrity of their U&C price reporting, but they persisted anyway.

Petitioners sued respondents in the Central District of Illinois in 2011, alleging that SuperValu’s reporting, and the resulting claims for reimbursement, violated the False Claims Act (FCA), which imposes liability on any person who knowingly presents, or causes to be presented, a false or fraudulent claim for payment. *See* 31 U.S.C. § 3729(a). While the case was pending, the Seventh Circuit held in *United*

*States ex rel. Garbe v. Kmart Corp.*, 824 F.3d 632, 645 (7th Cir. 2016), that prices under discount programs similar to SuperValu’s must be reported as U&C prices. The court further held that a pharmacy that fails to properly report U&C prices can be held liable under the FCA. *Id.* at 635. Based on this authority, the district court granted summary judgment to petitioners as to whether SuperValu’s claims for reimbursement were false. *See United States v. SuperValu, Inc.*, 2019 WL 3558483, at \*8 (C.D. Ill. Aug. 5, 2019).

The district court granted summary judgment to SuperValu, however, on the element of scienter, and a divided panel of the Seventh Circuit affirmed. As relevant here, the Seventh Circuit held that the FCA’s scienter element cannot be met when the defendant’s conduct comports with “an objectively reasonable reading of the statute or regulation” that it violated, and “there was no authoritative guidance warning against its erroneous view.” App. A at 20 (emphasis omitted). The Seventh Circuit further held that this is true even if the defendant did not hold its objectively reasonable view “at the time that it submitted its false claim.” *Id.* at 25. The court acknowledged that, under its interpretation, “defendants can avoid liability by concocting ‘post-hoc arguments’ to justify their conduct under an objectively reasonable reading of the applicable regulation—even if they acted in bad faith,” but held that the “defendant’s subjective intent does not matter for [the] scienter analysis” because “the inquiry is an objective one.” *Ibid.* Finding SuperValu’s interpretation of the U&C price term reasonable, and finding that no authoritative guidance warned SuperValu away from that interpretation, the Seventh Circuit

affirmed summary judgment for SuperValu on the element of scienter. *Ibid.* The dissent argued that the panel majority had misconstrued the FCA by allowing SuperValu to escape all liability despite record evidence showing that SuperValu knew that its claims for payment were likely false. *Id.* at 30 (Hamilton, J., dissenting).

Petitioners sought rehearing en banc, and the United States filed an amicus brief in support of that request. The government argued that the Seventh Circuit’s “unprecedented interpretation of the False Claims Act will significantly impair the government’s ability to combat fraud.” U.S. Reh’g Amicus Br. 5. The government explained that the Seventh Circuit’s rule conflicts with “circuit decisions holding that ambiguity in a requirement or applicable government guidance does not alone preclude a finding of knowledge” and “that warnings from non-governmental sources can put a defendant on notice of a likely violation.” *Id.* at 12. Highlighting the question’s practical importance, the government noted that this case implicates a “frequent fact pattern,” and described how the Seventh Circuit’s decision “encourages defendants to engage in ostrich-like behavior and places the burden on the government to anticipate every possible fraud.” *Id.* at 5, 12. The government also praised this case as a vehicle to consider the issue as it “presents a stark example of the kind of evidence the majority’s ruling will keep from a jury.” *Id.* at 13.

The Seventh Circuit denied rehearing en banc on December 3, 2021. App. B.

This application followed.

## REASONS FOR GRANTING AN EXTENSION OF TIME

The time to file a petition for a writ of certiorari should be extended for 29 days, to April 1, 2022, for several reasons.

First, the press of other matters will make submission of the petition difficult absent an extension. In addition to this petition, counsel for petitioners has been managing numerous recent and upcoming deadlines. The upcoming deadlines include:

- Representing the petitioners in Nos. 21-381, 21-382, and 21-462, all of which are cases in which this Court has called for the views of the Solicitor General, and counsel has been preparing presentations to the government as it determines its views
- February 23, 2022: Oral argument in *Jones v. Goodrich Pump & Engine Control Systems, Inc.*, No. 20-2951 (2d Cir.), a complex aviation tort case
- February 23, 2022: Response to a motion for certification under 28 U.S.C. § 1292(b) in *United States ex rel. Khoury v. Intermountain Healthcare, Inc.*, No. 2:20-cv-372-TC-CMR (D. Utah)
- February 28, 2022 (extension contemplated): Opening brief in *Hendrix v. J-M Manufacturing Co., Inc.*, No. 21-56276 (9th Cir.), an appeal following a full trial, where the lower court case has over 3000 docket entries
- March 11, 2022: Petition for a writ of certiorari in *O'Donnell & Sons, Inc. v. N.Y. State Dep't of Taxation & Finance*, No. 21A274
- March 18, 2022: Response to a motion to dismiss in *King v. Habib Bank Limited*, No. 20-cv-4322-LGS (S.D.N.Y), a complex case under the Anti-Terrorism Act
- March 21, 2022: Response to a petition for a writ of certiorari in *Molina Healthcare of Illinois, Inc. v. Prose*, No. 21-1145, a case under the False Claims Act
- March 25, 2022: Response to a motion to dismiss in *United States ex rel. Stenson v. Radiology Ltd., PLC*, No. 4:19-cv-306-JGZ-EJM (D. Ariz.), a case under the False Claims Act

- April 4, 2022: Opening brief in *Ivie v. AstraZeneca Pharmaceuticals, LP*, No. 21-35978 (9th Cir.), an appeal from a full trial

In addition to these upcoming work-related deadlines, my wife and I are expecting a baby, due on March 18, 2022 (no extensions allowed!).


Second, no prejudice would result from the requested extension. Whether the extension is granted or not, the petition can be considered this Term—and, if granted, the case will be argued and decided next Term. In the interim, the status quo *ante* remains intact. Respondents have kindly consented to the requested relief.

Finally, the petition is likely to be granted. As the government’s rehearing amicus brief shows, this case implicates a circuit split over an important question of federal law.

### CONCLUSION

For the foregoing reasons, the time to file a petition for a writ of certiorari should be extended for 29 days to and including April 1, 2022.

Respectfully submitted,



Tejinder Singh  
GOLDSTEIN & RUSSELL, P.C.  
7475 Wisconsin Ave.  
Suite 850  
Bethesda, MD 20814  
(202) 362-0636  
*tsingh@goldsteinrussell.com*

Dated: February 18, 2022

# **APPENDIX A**

In the  
United States Court of Appeals  
For the Seventh Circuit

---

No. 20-2241

UNITED STATES OF AMERICA ex rel. TRACY SCHUTTE, *et al.*,  
*Relators-Appellants,*

*v.*

SUPERVALU INC., *et al.*,  
*Defendants-Appellees.*

---

Appeal from the United States District Court for the  
Central District of Illinois.

No. 11-cv-3290 — **Richard Mills**, *Judge.*

---

ARGUED JANUARY 19, 2021 — DECIDED AUGUST 12, 2021

---

Before ROVNER, HAMILTON, and ST. EVE, *Circuit Judges.*

ST. EVE, *Circuit Judge.* This Court is no stranger to False Claims Act *qui tam* actions. The present appeal, however, contains a novel question for this Circuit: does the Supreme Court's interpretation of the Fair Credit Reporting Act's scienter provision in *Safeco Insurance Company of America v. Burr*, 551 U.S. 47 (2007), apply with equal force to the False Claims Act's scienter provision? We join the four circuits that have



answered that question in the affirmative and hold that it does.

This issue comes to us in a lawsuit against Defendants (collectively, “SuperValu”), which claims that SuperValu knowingly filed false reports of its pharmacies’ “usual and customary” (“U&C”) drug prices when it sought reimbursements under Medicare and Medicaid. SuperValu listed its retail cash prices as its U&C drug prices rather than the lower, price-matched amounts that it charged qualifying customers under its discount program. Medicaid regulations define “usual and customary price” as the price charged to the general public. Based on our decision in *U.S. ex rel. Garbe v. Kmart Corporation*, 824 F.3d 632 (7th Cir. 2016), the district court held that SuperValu’s discounted prices fell within the definition of U&C price and that SuperValu should have reported them. Relators Tracy Schutte and Michael Yarberry (the “Relators”) thus established falsity, the first prong of their False Claims Act (“FCA” or “the Act”) claims. On the scienter prong, however, the court applied the *Safeco* standard to the FCA and held that SuperValu did not meet it.

We agree that the scienter standard articulated in *Safeco* applies to the FCA. Here, as with the Fair Credit Reporting Act (“FCRA”), there is no statutory indication that Congress meant its usage of “knowingly,” or the scienter definitions it encompasses, to bear a different meaning than its common law definition. We further hold that while the FCA’s scienter provision is defined via three distinct definitions, a failure to establish the *Safeco* standard as a threshold matter precludes liability under any of these definitions. Applying this standard to the case at hand, SuperValu did not act with the

No. 20-2241

3

requisite knowledge under the FCA. The judgment of the district court is affirmed.

## **I. Background**

Underlying this case is a complex regulatory scheme, the details of which inform whether SuperValu has run afoul of the FCA's prohibition on submitting false claims to the government. Before canvassing the case facts, it is necessary to provide a brief overview of both the regulatory schemes under Medicare Part D and Medicaid and our FCA precedent involving those statutes.

### **A. Medicare Part D and Medicaid**

Medicare and Medicaid are government healthcare programs administered by the Department of Health and Human Services through the Centers for Medicare and Medicaid Services ("CMS"). Medicare Part D is a prescription drug benefit providing insurance coverage to beneficiaries. The government employs a multi-tier system to provide Medicare prescription subsidies. At the outset, CMS awards contracts to private plan sponsors to facilitate the benefits program and pays them directly, based in part on the number of enrolled beneficiaries. 42 U.S.C. § 1395w-115; 42 C.F.R. §§ 423.265, 423.315, 423.329(a), (c). Plan sponsors, in turn, enter agreements with pharmacies or with middlemen, known as Pharmacy Benefit Managers ("PBMs"), which deal directly with the pharmacies. The PBMs' contractual agreements with pharmacies specify the methods of calculating prescription drug rates for reimbursement claims, and the PBMs process claims and oversee reimbursements. *See* 42 U.S.C. § 1395w-111(i).

Medicare Part D limits prescription drug reimbursement rates to the lower of either the “actual charge” or “106 percent of the average sales price,” subject to specific limitations. 42 C.F.R. § 414.904(a). While federal regulations do not define “actual charge,” they do define “actual cost.” 42 C.F.R. § 423.100. The actual cost for a prescription from a “network pharmacy” means the “negotiated price” set by the PBM contract with that pharmacy. *Id.* If an out-of-network pharmacy prescribed the drug, the actual cost is the U&C price. *Id.* Medicare regulations define U&C price as the price charged to “a customer who does not have any form of prescription drug coverage.” *Id.* PBM contracts must comply with the Medicare Part D statute and regulations.

Medicaid operates in similar fashion but leverages the cooperative efforts of the states. 42 U.S.C. § 1396 *et seq.* The federal government and participating states jointly finance Medicaid, and the states implement the program through “state plans.” To be eligible for federal funding, a state’s plan must comply with the Medicaid statute and federal regulations and obtain approval from CMS. 42 U.S.C. §§ 1396-1, 1396a, 1396b. A state’s plan must describe the state agency’s “payment methodology for prescription drugs,” and the drug reimbursement methodology must comport with federal requirements for Medicaid expenditures. 42 C.F.R. § 447.518(a)–(b). Relevant here, federal regulations limit the pharmacy reimbursement for certain prescription drugs to the lower of either “[Actual acquisition cost] plus a professional dispensing fee” or providers’ “usual and customary charges to the general public.”<sup>1</sup> 42 C.F.R. § 447.512(b). Because both Medicare and

---

<sup>1</sup> While the state plans for the four states implicated in this appeal contain definitions of U&C price that have slight variances from the

No. 20-2241

5

Medicaid programs involve third-party submission of claims to the government, these reimbursement processes give rise to FCA litigation.

**B. *United States ex rel. Garbe v. Kmart Corporation***

We confronted one such FCA *qui tam* suit in *United States ex rel. Garbe v. Kmart Corporation*. In *Garbe*, we elaborated on the falsity prong of FCA claims in the context of U&C prices reported by pharmacies. The *Garbe* relator alleged that Kmart submitted false claims for prescription reimbursements under Medicare and Medicaid by failing to report its discount-program prices as its U&C prices. *Garbe*, 824 F.3d at 636. Instead, Kmart had reported the higher prices it charged to third-party insurers and non-program cash customers. *Id.* The district court disposed of the relator's FCA claim on a motion for partial summary judgment. On interlocutory appeal, we added the question whether the district court correctly held that Kmart's discount-program prices were U&C prices—the prices “charged to the general public.” *Id.* at 637. We affirmed that determination.

Our decision referenced a variety of sources—dictionary definitions, regulatory definitions, Medicare policy, caselaw, and a CMS manual—to determine the boundaries of “usual and customary price charged to the general public.” We noted that unless state regulations provided a different meaning, the U&C price “is defined as the ‘cash price offered to the general public.’” *Id.* at 643. Upon consideration of these sources and the case facts, we determined that Kmart's program fell

---

wording in § 447.512(b), the Relators have stipulated that these definitions are substantively equivalent to the federal definition. We consequently analyze the federal definition of U&C price for purposes of this appeal.

within the scope of “U&C price.” Kmart’s generic-drug discount program offered set prices and was open to the public—any customer could opt in by paying a \$10 fee and providing personal information. *Id.* at 643. The discount prices were “the lowest prices for which its drugs were widely and consistently available”—over 89% of Kmart’s cash customers received the discount prices. *Id.* at 635, 645; *U.S. ex rel. Garbe v. Kmart Corp.*, 73 F. Supp. 3d 1002, 1018 n.10 (S.D. Ill. 2014). We also found it significant that Kmart had offered these prices for several benefit years rather than as “a one-time ‘lower cash’ price.” *Garbe*, 824 F.3d at 644. On those facts, we held that a pharmacy’s discount-program prices could be its U&C prices when the program was offered to the public, even though the discount prices were not the retail prices charged to all customers. *Id.* at 645. We remanded *Garbe* without discussing the FCA’s scienter prong. Although the scienter prong is at issue in this appeal, *Garbe* played a key role in the suit against SuperValu.

### C. Factual Background

SuperValu, through several subsidiaries, operated or controlled roughly 2,500 grocery stores with over 800 in-store pharmacies between 2006 and 2016. In 2006, SuperValu’s national headquarters implemented the discount program underlying this appeal, which ran until December 2016. The price-match initiative was an attempt to compete with pharmacies such as Wal-Mart, which had launched a discount program that same year offering hundreds of generic drugs at \$4 per 30-day prescription. SuperValu sought to remain competitive without adopting Wal-Mart’s program. According to SuperValu’s Vice President of Prescription Services, implementing a \$4 generics program would cost SuperValu \$40–\$50

No. 20-2241

7

million in losses if \$4 was the U&C cost passed on to PBMs. Instead, SuperValu employed what it internally characterized as a “stealthy’ approach.” Corporate officers framed SuperValu’s price-match program as an “exception’ for customer service reasons” that would not be reported as the U&C price.

Under SuperValu’s price-match program, its regional stores could match lower prices on prescription drugs offered by other, local pharmacies within a specific proximity to the regional store. But the discount was not automatic. Customers had to request a price match. Once SuperValu pharmacists verified the competitor’s price, SuperValu automatically applied the discount for that customer on future refills.<sup>2</sup> Any customer could request a price match, including those with insurance or government healthcare plans. When applying a price-match cost for insured customers, the pharmacists overrode the price in the pharmacy’s automatic system and manually entered the price-matched cost. SuperValu instructed pharmacies to process these price-match sales as cash transactions rather than third-party payor claims that would go directly to insurers.

SuperValu did not report these price-matches when it submitted reimbursement claims to third-party insurers, including Medicare Part D and Medicaid. Rather, SuperValu listed its retail price—the price for uninsured cash customers—as its U&C price. Many of SuperValu’s PBM contracts contained U&C price clauses, but the contractual definitions of that term varied. Some contracts addressed reporting prices from

---

<sup>2</sup> SuperValu did not implement its automatic price override until 2008. All SuperValu’s pharmacies had ceased the price-match program by December 2016, a few months after this Court decided *Garbe* in May 2016.

discount programs, either including discount programs as a blanket rule or excepting specific types of discounts. Others did not mention discounts at all. None of the contracts expressly included price-matching, although one PBM, Medco, stated in its 2007–2008 manual that it included a “competitor’s matched price” in its definition of U&C price.

Between 2006 and 2016, sales under SuperValu’s price-matching policy accounted for 26.6% of SuperValu’s cash drug sales and 1.69% of its total prescription drug sales—roughly 6.3 million sales. In 2012, the majority of the cash sales for 44 of SuperValu’s top 50 prescription drugs were made at a price-match cost rather than SuperValu’s retail price.<sup>3</sup> SuperValu continued its price-match program until December 2016 and did not report its discount prices as its U&C prices to any PBM or state agency during that time.

#### **D. Procedural Background**

In 2011, the Relators filed this suit against SuperValu under the FCA on behalf of the federal government and several states.<sup>4</sup> They alleged that SuperValu knowingly caused false payment claims to be submitted to government healthcare programs between 2006 and 2016 by incorrectly reporting their U&C drug prices. The Relators’ theory of the case was

---

<sup>3</sup> The dissent cites this statistic without confining it to fiscal year 2012. We note that the Relators have identified no evidence regarding the frequency of price-match sales versus retail cash sales for SuperValu’s top 50 drugs during any of the other years between 2006-2016 when its price-match program was active.

<sup>4</sup> In the district court, the parties stipulated to a dismissal of all Medicaid claims on behalf of the states except those on behalf of California, Illinois, Utah, and Washington.

No. 20-2241

9

that SuperValu price-matched to avoid losing customers to competitors with lower drug prices like Wal-Mart and made up the difference by charging government healthcare programs its higher, retail price. In effect, the Relators argued, SuperValu caused the government to subsidize its market competitiveness. The government did not intervene in this case.

The district court, relying on *Garbe*, granted summary judgment to the Relators on the falsity prong.<sup>5</sup> It acknowledged that SuperValu's price-match program required customers to initiate a discount and found that discount sales comprised a lower portion of SuperValu's sales—roughly 2% of total transactions and 26.9% of cash sales—compared to Kmart's discounts in *Garbe*, which amounted to 89% of its cash sales. Even so, the court held that the fact that SuperValu made its price-match policy *available* to the general public throughout a benefit year was determinative.

In a separate order, the district court sided with SuperValu on the scienter prong. The court first applied *Safeco's* standard to the FCA's scienter prong and held that a failure to establish the objective scienter standard precluded liability under the FCA. Under the *Safeco* standard, the court held that SuperValu's understanding of U&C price, while incorrect, was objectively reasonable at the time. The district court first observed that there were multiple district court decisions endorsing SuperValu's view of U&C price or recognizing that the term was open to interpretation. It also took note of the unique circumstance in which *Garbe* addressed the definition

---

<sup>5</sup> SuperValu does not contest the district court's falsity holding in this appeal.



of U&C price. Because the Seventh Circuit added that question to the issues certified for interlocutory appeal, the district court suggested that we must have found the matter “sufficiently debatable to be addressed.”

Based on the available caselaw, the court held that it was unclear that SuperValu’s program fell within the U&C definition. Further, the court held that prior to our 2016 decision in *Garbe*, there was no authoritative guidance to warn SuperValu away from its interpretation of U&C price. In view of these conclusions, the district court entered summary judgment for SuperValu on all FCA claims, which the Relators now challenge.

## II. Discussion

On appeal, the parties ask us to determine whether *Safeco* applies to the FCA’s scienter standard and, if so, to what extent. Our answers to those questions will dictate the outcome of the final issue in this appeal—whether the district court properly granted summary judgment for SuperValu on the scienter prong of the FCA claim. We review the district court’s determinations on these legal issues *de novo* and affirm the grant of summary judgment to SuperValu. *Bigger v. Facebook, Inc.*, 947 F.3d 1043, 1048, 1051 (7th Cir. 2020).

### A. The False Claims Act

The FCA imposes civil liability on any person who “knowingly presents, or causes to be presented, a false or fraudulent claim for payment or approval.” 31 U.S.C. § 3729(a)(1)(A). FCA civil claims thus require proof of two primary elements: (1) falsity and (2) scienter. The Supreme Court has also interpreted § 3729(a)(1)(A) to require that knowingly false claims be material to the government’s payment decision for liability

No. 20-2241

11

to attach. *Univ. Health Servs., Inc. v. U.S. ex rel. Escobar*, 136 S. Ct. 1989, 1996 (2016).

Although “Congress did not define what makes a claim ‘false’ or ‘fraudulent,’” the Supreme Court has applied the common law meaning of fraud to these terms as they are used in the FCA. *Id.* at 1999. Under that definition, a claim may be false or fraudulent through either express misrepresentations or “misrepresentations by omission.” *Id.*

Unlike the falsity prong, the FCA’s scienter requirement is statutorily defined. A party who submits a false claim to the government is on the hook for FCA liability only if it acted knowingly. § 3729(a)(1)(A). The FCA defines knowingly to “mean that a person, with respect to information (i) has actual knowledge of the information; (ii) acts in deliberate ignorance of the truth or falsity of the information; or (iii) acts in reckless disregard of the truth or falsity of the information.” § 3729(b)(1)(A). It “require[s] no proof of specific intent to defraud.” § 3729(b)(1)(B). The FCA levies significant consequences against parties found liable under the Act and balances the severity of its penalties by carefully circumscribing liability, in part through its scienter requirement. *See Escobar*, 136 S. Ct. at 1995–96 (observing that FCA civil “liability is essentially punitive in nature” (internal quotation omitted)).

#### **B. *Safeco Insurance Company of America v. Burr***

While the FCA lists the range of scienter levels encompassed by “knowingly,” it does not further define those terms. SuperValu urges us to look to the Supreme Court’s decision in *Safeco* for guidance. *Safeco* involved an interpretation of the FCRA’s common law scienter requirement, under which plaintiffs must show that defendants acted “willfully.” 15

U.S.C. § 1681n(a). As defined by the Court, the FCRA's use of that term includes both "knowing" and "reckless disregard." *Safeco*, 551 U.S. at 52, 59.

In interpreting the FCRA's scienter prong, the Court first observed "the general rule that a common law term in a statute comes with a common law meaning, absent anything pointing another way." *Id.* at 58. Finding none, it employed what amounts to a two-step inquiry for determining reckless disregard. *Id.* at 69. A defendant who acted under an incorrect interpretation of the relevant statute or regulation did not act with reckless disregard if (1) the interpretation was objectively reasonable and (2) no authoritative guidance cautioned defendants against it. *Id.* at 70. Critically, the Court emphasized that a defendant's subjective intent is irrelevant for purposes of liability. *Id.* at 68, 70 n.20. The Court also explained that failure to meet this standard would preclude a finding of knowing violations as well. *Id.* at 70 n.20.

The Court then applied that standard and held that while *Safeco* may have violated the FCRA, it did not do so with reckless disregard. The FCRA requires that any person who takes an "adverse action" against a consumer based on information in a consumer report notify that consumer. 15 U.S.C. § 1681m(a). An "adverse action" is statutorily defined as including "an increase" in the amount charged for "insurance, existing or applied for." § 1681a(k)(1)(B)(i). The *Safeco* plaintiffs argued that *Safeco* violated the FCRA when it offered new insurance applicants higher rates without notifying them that their credit scores triggered the less favorable policy offers. *Safeco*, 551 U.S. at 55. *Safeco* thought initial rate offers to new customers fell outside FCRA notice obligations because

No. 20-2241

13

it interpreted “increase” to mean rate hikes on existing policies. *Id.* at 69–70.

While Safeco’s interpretation was erroneous, the Court held that it was objectively reasonable. Why? Because Safeco’s “reading ha[d] a foundation” in “the less-than-pellucid statutory text.” *Id.* Further, there was no court of appeals decision or authoritative guidance from the Federal Trade Commission—the agency charged with enforcing the FCRA—that “might have warned it away from the view it took.” *Id.* at 70. Under the Court’s two-step inquiry, these facts precluded a finding of reckless disregard. Since this decision, four circuit courts have applied the *Safeco* standard to the FCA’s scienter prong. SuperValu asks us to do the same today.

### C. *Safeco* applies to the FCA

To determine what the FCA’s scienter provision requires, we “start, as always, with the statutory text.” *Escobar*, 136 S. Ct. at 1999. The FCA defines “knowingly” as encompassing three common law standards—actual knowledge, deliberate indifference, and reckless disregard—but is silent as to what those standards mean in the context of this statute.<sup>6</sup> Supreme Court precedent teaches that “a common law term in a statute comes with a common law meaning, absent anything pointing another way.” *Safeco*, 551 U.S. at 58. That principle informs our decision today. Here, the Relators have identified no statutory indicia that Congress intended the familiar, common

---

<sup>6</sup> The FCA imposes civil liability. We thus reference the civil, not criminal, definitions of these scienter standards throughout our discussion. *Safeco*, 551 U.S. at 60 (acknowledging distinctions between criminal and civil uses of the same scienter terms and indicating that criminal law usage has no bearing on the definitions of these terms when used in civil laws).

law terms used in § 3729 to differ from their common law meaning. Indeed, the Supreme Court has confirmed that the FCA does employ the common law meaning for other common law terms—“false” and “fraudulent”—and has limited the common law definition only to the extent that the statute expressly contradicted it. “Congress retained all other elements of common-law fraud that are consistent with the statutory text because there are no textual indicia to the contrary.” *Escobar*, 136 S. Ct. at 1999 & n.2. Given that the common law meaning applies to the FCA’s scienter standard, all that remains is to identify that meaning. We need look no further than the Supreme Court’s decision in *Safeco*.

*Safeco* defined a similar common law term—“willfully,” as used in the FCRA—which the Court interpreted as encompassing the same common law scienter terms used in the FCA (“knowingly” or “reckless disregard”). Referencing the common law meaning, the Court then announced a standard inquiry for reckless disregard. While reiterating that “knowingly” and “reckless disregard” remain distinct terms, the Supreme Court held that the objective scienter standard it articulated precluded liability under either term. *Safeco*, 551 U.S. at 60, 70 n.20. There is no reason why the scienter standard established in *Safeco* (for violations committed knowingly or with reckless disregard) should not apply to the same common law terms used in the FCA.

The dissent suggests that *Safeco* has no bearing simply because it interpreted a different scienter requirement in a different statute. We respectfully disagree. *Safeco* articulated an objective scienter standard for establishing willful violations, which it framed in terms of the scienter floor for that standard—reckless disregard. Likewise, reckless disregard is the

No. 20-2241

15

baseline scienter definition encompassed by the FCA's scienter requirement, "knowingly." *United States v. King-Vassal*, 728 F.3d 707, 712 (7th Cir. 2013) (observing that reckless disregard "is the most capacious of the three" terms used to define the FCA's scienter requirement). And *Safeco* explicitly held that the test for reckless disregard would likewise cover violations committed "knowingly." *Safeco*, 551 U.S. at 70 n.20. In view of those parallels, we see no barrier to importing the *Safeco* standard to the FCA. See *Purcell*, 807 F.3d at 284, 290.

Every other circuit court to discuss the relevance of *Safeco*'s scienter standard to the FCA has arrived at this conclusion. *United States ex rel. Streck v. Allergen*, 746 F. App'x 101, 106 (3d Cir. 2018); *United States ex rel. McGrath v. Microsemi Corp.*, 690 F. App'x 551, 552 (9th Cir. 2017); *United States ex rel. Donegan v. Anesthesia Assocs. of Kan. City, PC*, 833 F.3d 874, 879–80 (8th Cir. 2016); *United States ex rel. Purcell v. MWI Corp.*, 807 F.3d 281, 284 (D.C. Cir. 2015). The dissent claims that the Eleventh Circuit declined to apply *Safeco* to the FCA in *United States ex rel. Phalp v. Lincare Holdings, Inc.*, 857 F.3d 1148 (11th Cir. 2017). But *Phalp* did not reject *Safeco*—it did not even cite *Safeco*. To support its conclusion, the dissent points to *Phalp*'s assertion that "scienter is not determined by the ambiguity of a regulation, and can exist even if a defendant's interpretation is reasonable." *Id.* at 1115. That is not inconsistent with *Safeco*. Under *Safeco*, an objectively reasonable interpretation of a statute or regulation does not shield a defendant from liability if authoritative guidance warned the defendant away from that interpretation. Regardless of differing views as to whether *Phalp* is consistent with the *Safeco* standard, the Eleventh Circuit did not reject *Safeco*'s applicability to the FCA. Even though the parties briefed the court on *Safeco*, that briefing does not convert the Eleventh Circuit's silence into a

decision that *Safeco* does not apply to the FCA. As it stands, no circuit has held *Safeco* inapplicable to the FCA.

The dissent would part ways with the circuits that have applied the *Safeco* standard to the FCA and look instead to the Restatement (Second) of Torts § 526, which makes subjective intent relevant to the scienter inquiry. Section 526 defines “conditions under which misrepresentation is fraudulent.” It does not define “knowingly” (or any of the common law scienter terms listed in § 3729(b)(1)(A)). And it is a different provision than the Restatement provision that the Court referenced in *Safeco*, 551 U.S. at 69 (relying upon § 500, defining “reckless disregard”). We thus disagree that § 526 is relevant to the FCA’s scienter provision. Take out “knowingly,” and perhaps it makes sense to read general, common law fraudulent scienter into the Act. But here, Congress *has* willed a specific scienter requirement—knowingly, not “‘knowing’ of falsity,” as the dissent suggests.

Unlike § 526, § 500 defines a term that the FCA’s definition of knowingly expressly includes (“reckless disregard”). The dissent insists that because § 500—which defines “reckless disregard of safety”—applies to cases involving physical harm, it is inapplicable to “reckless disregard” as used in the FCA. But the Supreme Court applied this definition outside the physical-harm context in *Safeco*. Ultimately, the crucial point is that the Court has articulated a standard for acts committed “knowingly” or with “reckless disregard” that excludes subjective intent. In the absence of textual indicia in the FCA supporting that subjective intent matters here, we apply Supreme Court precedent to interpret the same common law terms addressed in *Safeco*.

No. 20-2241

17

While the dissent claims that its countervailing view is textually mandated, nothing in the language of the FCA suggests that a defendant's subjective intent is relevant. In contrast to § 526, terms such as "believes" or "have [] confidence" are conspicuously absent from the FCA, and the only reference to intent is an express disclaimer that "specific intent to defraud" is irrelevant. § 3729(b)(1)(B). We decline to graft aspects of common law fraudulent scienter into the FCA when Congress chose not to include such requirements.

The dissent instead looks to legislative history and out-of-circuit caselaw to support its reading of the FCA. We find neither source persuasive. Legislative history cannot support reading in a subjective-intent requirement that goes beyond the text of the Act's scienter provision. *See Chamber of Commerce of U.S. v. Whiting*, 563 U.S. 582, 599 (2011) ("Congress's authoritative statement is the statutory text, not the legislative history." (internal citation and quotation omitted)). And the circuit cases upon which the dissent relies all predate *Safeco*, as well as subsequent caselaw in each of those circuits applying *Safeco* to the FCA. Neither Restatement § 526 nor legislative history pose a barrier to applying *Safeco*.

The Relators challenge *Safeco*'s viability on a separate basis that likewise fails. They contend that subsequent Supreme Court precedent limited *Safeco*, leaning on a 2016 patent case for this premise—*Halo Electronics, Inc. v. Pulse Electronics, Inc.*, 136 S. Ct. 1923 (2016). *Halo Electronics* interpreted § 284 of the Patent Act, which provides that courts may award treble damages in infringement cases. Section 284 does not specify a scienter standard, and prior to *Halo Electronics*, the Federal Circuit required plaintiffs to show that an infringer's conduct was "both objectively baseless and brought in subjective bad



faith.” *Id.* at 1932–33. *Halo Electronics* clarified that § 284 liability does not depend on objective recklessness.

The problem with importing an objective recklessness inquiry into the patent context was that “such a defense insulates the infringer from enhanced damages, even if he did not act on the basis of the defense or was even aware of it.” *Id.* at 1933. In rejecting that standard, the Court emphasized that the Patent Act targets “consciously wrongful” bad action and held that “[i]n the context of such deliberate wrongdoing, however, it is not clear why an independent showing of objective recklessness ... should be a prerequisite to enhanced damages.” *Id.* at 1932.

The defendants, citing *Safeco*, argued that bad faith is irrelevant when there is no showing of objective recklessness. *Id.* at 1933 n.\*. While acknowledging the *Safeco* standard, the Court declined to apply it. It observed that “willfully is a word of many meanings whose construction is often dependent on the context in which it appears.” *Id.* (internal quotation omitted). The Patent Act presented a different context than the FCRA: “[O]ur precedents make clear that ‘bad-faith infringement’ is an independent basis for enhancing patent damages.” *Id.*

The Supreme Court thus did not walk back *Safeco* or adopt a new standard for objective recklessness. *Halo Electronics* simply did not apply objective recklessness in the context of a statute focused on defendants’ subjective bad faith. The reasons informing that decision do not apply here. Unlike the Patent Act, the FCA expressly includes a scienter standard and limits liability to knowingly false claims. By its own terms, *Safeco* holds that a failure to establish its objective scienter standard precludes a finding that a defendant acted

No. 20-2241

19

knowingly. We thus hold that *Safeco's* scienter standard applies to the FCA.

**D. Failure to meet the *Safeco* standard precludes liability**

Beyond the threshold question of *Safeco's* applicability to the FCA, the parties also dispute how broadly *Safeco* reaches. We agree with SuperValu that the *Safeco* standard reaches all three of the scienter terms that define “knowingly.” The dissent takes the Relators’ position that even if it is relevant to the FCA, *Safeco* defines only “reckless disregard.” Under this view, failure to show that a defendant meets the *Safeco* standard does not preclude liability under the actual knowledge or deliberate ignorance components of the FCA’s scienter definition. The dissent contends that holding otherwise would collapse distinct scienter terms and violate the rule against surplusage. We are unconvinced.

The Supreme Court has already undermined this line of reasoning. In *Safeco*, the Court rejected the defendants’ argument that it was conflating scienter terms and reaffirmed that the terms it used to define “willfully” were distinct. *Safeco*, 551 U.S. at 60. (“[A]ction falling within the knowing subcategory does not simultaneously fall within the reckless alternative.”). It nevertheless held that the standard it articulated in the context of “reckless disregard” also functioned as a baseline requirement for establishing the more demanding scienter category of “knowledge.” *Id.* at 70 n.20 (“Where, as here, the statutory text and relevant court and agency guidance allow for more than one reasonable interpretation, it would defy history and current thinking to treat a defendant who merely adopts one such interpretation as a *knowing or reckless* violator.” (emphasis added)). That holding nullifies the dissent’s contention.

Even aside from *Safeco's* dismissal, the dissent's argument rests upon a false equivalence. No one disputes that the three scienter terms used to define "knowingly" are distinct and bear different meanings. Both actual knowledge and deliberate ignorance indicate higher degrees of culpability and, if implicated in a case, might render reckless disregard inapplicable. See *Purcell*, 807 F.3d at 288 (observing that reckless disregard is the loosest standard of knowledge under the FCA's scienter requirement). That does not prevent these terms, however, from sharing a common requirement.

Indeed, we do not see how it would be possible for defendants to actually know that they submitted a false claim if relators cannot establish the *Safeco* scienter standard. A defendant might suspect, believe, or intend to file a false claim, but it cannot *know* that its claim is false if the requirements for that claim are unknown. The dissent's primary concern that the *Safeco* standard eliminates culpability for deliberately indifferent defendants is likewise misplaced. The dissent postulates that under the *Safeco* standard, defendants could escape liability by making a "barely plausible" post-hoc argument about a statute's meaning, "even though the defendant ignored repeated and correct warnings." That fundamentally misapprehends *Safeco*. Under *Safeco*, a defendant will be successful only if (a) it has an *objectively* reasonable reading of the statute or regulation and (b) there was no authoritative guidance warning against its erroneous view. That test does not shield bad faith defendants that turn a blind eye to guidance indicating that their practices are likely wrong. Nor does *Safeco's* standard excuse a company if its executive decisionmakers attempted to remain ignorant of the company's claims processes and internal policies. *Safeco* covers all three of the scienter standards listed in § 3729. When relators cannot

No. 20-2241

21

establish the standard articulated in *Safeco*, there is no liability under the FCA.

**E. SuperValu’s interpretation of “usual and customary price” was objectively reasonable under *Safeco***

Although the *Safeco* Court did not express its standard for reckless disregard in terms of elements, the Court’s objectively reasonable inquiry involved two distinct questions—whether the defendant has a permissible interpretation of the relevant provision and whether authoritative guidance nevertheless warned it away from that reading.<sup>7</sup>

**1. Permissible Interpretation**

The objectively reasonable inquiry hinges on the text of the statute or regulation that the defendant allegedly violated and as such is a question of law. *Safeco*, 551 U.S. at 69; *see also Van Straaten v. Shell Oil Prods. Co. LLC*, 678 F.3d 486, 489–90 (7th Cir. 2012). If the plain language of the statute precludes the erroneous interpretation, the defendant cannot clear this hurdle. To decide whether SuperValu had a permissible interpretation of U&C price, we must first determine the source of that term and relevant definition.

---

<sup>7</sup> Some courts have divided the *Safeco* inquiry into three steps, adding as a preliminary question whether the relevant text is ambiguous. *Donegan*, 833 F.3d at 878; *Purcell*, 807 F.3d at 288. We elect to condense the inquiry into the two issues expressly discussed in *Safeco*—permissible interpretation and authoritative guidance. The *Safeco* Court did not require a separate determination of ambiguity, and we think that the issue of textual ambiguity is subsumed within the permissible-interpretation inquiry. A defendant’s erroneous interpretation cannot be reasonable if the meaning of the text is unambiguous.

Medicaid regulations define U&C price without much elaboration as the price that a pharmacy “charges to the general public.”<sup>8</sup> 42 C.F.R. § 447.512(b); *see also Garbe*, 824 F.3d at 643–44. Federal regulations do not elaborate beyond that cursory definition or guide pharmacies on identifying the “general public” when they charge customers various prices for the same prescription.<sup>9</sup> “Usual and customary” might mean the price that is “charged” most frequently for a drug, but it could also indicate the retail rather than discount price. *See* GAO, Report to Congress on Trends in Usual and Customary Prices for Drugs Frequently Used by Medicare and Non-

---

<sup>8</sup> The Relators argue that for Medicare, pharmacies that have contracted with a plan sponsor or PBM report the “negotiated price” determined by the contract. On appeal, the Relators consequently look to the various formulations of U&C price in SuperValu’s PBM contracts. In the district court, however, they took the opposite position: “Relators dispute that the contracts between PBMs and pharmacies ‘govern the terms’ by which Defendants are required to submit claims to the PBMs and in turn, whether and how much the PBMs should pay Defendants for dispensing drugs to their beneficiaries.” Relators’ Resp. to Defs.’ Mot. for Partial Summ. J. at 9 [191-1]. As a result, they have waived any argument on appeal that the contractual definitions of U&C price are distinct from the Medicaid regulatory definition. We thus examine only § 447.512(b)’s definition of U&C price and treat the PBM contract definitions of U&C price as consistent with it.

<sup>9</sup> The Relators also identified four states’ regulations defining U&C price, as Medicaid is implemented through the states. The regulations that were concurrent with SuperValu’s price-match program used substantially the same definition of U&C price as 42 C.F.R. § 447.512(b). The Relators also claim that they are “consistent with the controlling federal definition and the U&C framework analyzed in *Garbe*.” We consequently treat our analysis of the federal definition of U&C price as extending to these states and the FCA claims related to Medicaid.

No. 20-2241

23

Medicare Enrollees at 1 (Oct. 6, 2004) (“The usual and customary price is the undiscounted price individuals without drug coverage would pay.”). “General public” may mean that discount prices qualify only if applied to all consumers or, alternatively, if they constitute the price most frequently charged to consumers. But it just as easily might encompass any discount program *offered* to the public, regardless of whether all consumers take advantage of it. *Garbe*, 824 F.3d at 643. As is, the U&C price definition is open to multiple interpretations.

Here, SuperValu interpreted its set, retail price for a prescription drug as the “price it charges to the general public.” Unlike its retail price, the discount prices under SuperValu’s price-match program depended upon the prices charged by local competitors and initially applied only upon customer request. In short, while its program was available to any customer requesting a valid price match, SuperValu would not necessarily charge all or most of its customers lower, price-matched costs. SuperValu thus did not view its competitor price-matching as the price that it “charged to the general public.” That interpretation is not inconsistent with the text of the U&C price definition. *See Garbe*, 824 F.3d at 644 (citing § 447.512(b)).

The Relators spend little time discussing the compatibility of SuperValu’s interpretation of U&C price with the regulatory text. Instead, they contend that *Garbe* forecloses any argument on objective reasonableness. *Garbe* characterized the federal regulations at issue here as having a “clear” purpose—ensuring that the government receives the benefit of the “prevailing retail market price” that pharmacies provide to consumers. *Garbe*, 824 F.3d at 644. From this, the Relators claim that we have already held that the meaning of

U&C price is unambiguous. The flaws in this argument are two-fold.

As an initial matter, it overextends our holding in *Garbe*. *Garbe* held that the correct interpretation of U&C price included certain discount program prices—it did not hold that this was the *only* objectively reasonable interpretation of the term. In fact, *Garbe* did not discuss *Safeco* at all. We had no reason to do so because we explicitly did not address the FCA’s scienter prong. The decision that we did reach in *Garbe*—interpreting “U&C price”—does not influence the objectively reasonable inquiry here, either. *Safeco*’s scienter standard has bite only if a defendant’s interpretation may be objectively reasonable even if it is erroneous. That Super-Valu’s interpretation of U&C price is incorrect under *Garbe* does not de facto render its interpretation unreasonable.

The Relators also err by calibrating objective reasonableness against the clarity of a statute or regulation’s policy objective. Their *Garbe* argument rests on the assumption that any regulation with a clear *purpose* cannot be ambiguous. But *Safeco* tethered the objectively reasonable inquiry to the legal text, not its underlying policy. *Safeco*, 551 U.S. at 69–70 (holding that *Safeco*’s erroneous interpretation was reasonable because it had a foundation in the “less-than-pellucid” statutory text). The Relators’ failure to engage with the regulatory text is fatal to their objections. They have not shown that Super-Valu’s erroneous interpretation of U&C price was unreasonable.

Apart from the Relators’ arguments based on *Garbe*, the dissent suggests a more fundamental concern with Super-Valu’s interpretation of U&C price. It argues that for an erroneous interpretation to be objectively reasonable, the

No. 20-2241

25

defendant must have held that view at the time that it submitted its false claim.<sup>10</sup> Otherwise, the dissent insists, defendants can avoid liability by concocting “post-hoc arguments” to justify their conduct under an objectively reasonable reading of the applicable regulation—even if they acted in bad faith. The dissent essentially argues that SuperValu believed it was violating the requirement to report its U&C price and arrived at its “interpretation” of U&C price after the fact.

Even if the Relators can raise an issue of fact on this point, it is irrelevant. The FCA establishes liability only for *knowingly* false claims—it is not enough that a defendant suspect or believe that its claim was false. *See Purcell*, 807 F.3d at 288 (holding that defendants did not violate the FCA because they “could reasonably have concluded” that their conduct complied with the law, even though they believed—and testified that they “knew”—it did not). Indeed, *Safeco* emphasized that a defendant’s subjective intent does not matter for its scienter analysis—the inquiry is an objective one. This standard reflects the limits of FCA liability. *See Escobar*, 136 S. Ct. at 2003 (“The False Claims Act is not an all-purpose antifraud statute or a vehicle for punishing garden-variety breaches of contract or regulatory violations.” (cleaned up)). We apply the standard as we find it and hold that SuperValu has offered an objectively reasonable interpretation of U&C price.

---

<sup>10</sup> The dissent does not—and cannot—rely on *Safeco* for this assertion. *Safeco* made no mention of a temporal requirement when it articulated the objectively reasonable inquiry. The Relators cited *Halo Electronics* when they raised this same argument on appeal. But as explained previously, we reject the applicability of that case to the FCA.



## 2. Authoritative Guidance

This moves SuperValu but halfway across the scienter line. *Safeco* makes clear that a permissible interpretation is no defense if there existed authoritative guidance that should have warned defendants away from their erroneous interpretation.<sup>11</sup> “Authoritative guidance,” as the moniker implies, must come from a source with authority to interpret the relevant text. *Safeco* also suggests that the guidance must be sufficiently specific to the defendant’s incorrect interpretation.

The Supreme Court did not flesh out the boundaries of authoritative guidance, but at minimum, *Safeco* supports that it must come from a governmental source—either circuit court precedent or guidance from the relevant agency.<sup>12</sup> *Safeco*, 551 U.S. at 70. We are not alone in this view. Other circuit courts likewise have limited authoritative guidance to these two sources. See *Purcell*, 807 F.3d at 289 (considering only circuit court caselaw and guidance from the controlling agency); *Streck*, 746 F. App’x at 106, 108 (same). Our reading of *Safeco* automatically excludes one of the three sources of guidance proposed by the Relators—the PBM contract definitions of U&C price. The Relators also identify federal and state regulations defining U&C price, but we have considered the relevant regulatory definition above and determined that it does

---

<sup>11</sup> The authoritative-guidance inquiry is a question of law in this case, as it entails only the interpretation of regulatory guidance.

<sup>12</sup> The parties agree that *Garbe* is no help to the Relators on this front, despite its status as circuit court precedent that would otherwise constitute authoritative guidance. Recall that we decided that case in May 2016, the same year that SuperValu shelved its discount program. The Supreme Court did not deny the *Garbe* certiorari petition until 2017.

No. 20-2241

27

not preclude SuperValu's interpretation. As a result, those definitions cannot constitute warnings that SuperValu's interpretation was erroneous.

The remaining source of guidance identified by the Relators is the CMS Medicare Prescription Drug Benefit Manual ("CMS manual" or "manual"). The Relators contend that the manual constitutes authoritative guidance which should have warned SuperValu that its discount prices amounted to U&C prices. SuperValu responds that it did not, for two reasons. First, SuperValu suggests that the manual is not "authoritative" guidance as defined by *Safeco*. It reads *Safeco* to require that authoritative agency guidance not only originate from the agency charged with implementing the relevant statute but that it be binding on the agency, such as notice-and-comment rulemaking or agency adjudication. The circuits that have addressed *Safeco*'s applicability to the FCA appear split on this question. But we need not—and do not—decide this matter today because we agree with SuperValu's second argument: the CMS manual was not sufficiently specific to warn SuperValu that its program likely would fall within the definition of U&C price.

*Safeco* suggests that authoritative guidance must have a high level of specificity to control an issue. In *Safeco*, the agency guidance at issue was an FTC letter to Safeco explaining that an adverse action "occurs when 'the applicant will have to pay more for insurance at the inception of the policy than he or she would have been charged if the consumer report had been more favorable.'" *Safeco*, 551 U.S. at 70 n.19 (internal citation omitted). That guidance certainly related to the question on appeal—whether an "increase" in insurance rates based on a consumer report could "be understood without

reference to prior dealing (allowing a first-time applicant to sue)." *Id.* at 64–65. Nevertheless, the Supreme Court rejected the FTC letter in part because the Court thought that it "did not canvass the issue."<sup>13</sup> *Id.* at 70 n.19.

Upon review of the CMS manual, we conclude that it is similarly flawed. Footnote one of the manual is most salient and reads in relevant part as follows:

We note that in cases where a pharmacy offers a lower price to its customers throughout a benefit year, this would not constitute a "lower cash price" situation that is the subject of this guidance. For example, Wal-Mart recently introduced a program offering a reduced price for certain generics to its customers. The low Wal-Mart price on these specific generic drugs is considered Wal-Mart's "usual and customary" price, and is not considered a one-time "lower cash" price. Part D sponsors consider this lower amount to be "usual and customary" and will reimburse Wal-Mart on the basis of this price.

CENTERS FOR MEDICARE & MEDICAID SERVICES, *Chapter 14—Coordination of Benefits, in* MEDICARE PRESCRIPTION DRUG BENEFIT MANUAL 19 n.1 (2006), <https://perma.cc/MW6AH4P6>.

The footnote clarifies that a pharmacy's consistent, lower-price offers are included within U&C prices. But it says nothing about price-match programs like that employed by

---

<sup>13</sup> The Court's other reason for considering the letter unauthoritative was that the FTC had expressly stated that it was not binding on the agency. *Safeco*, 551 U.S. at 70 n.19.

No. 20-2241

29

SuperValu. Further, the majority of the footnote discusses a specific example—Wal-Mart’s \$4 generics program—which differed in significant respects from SuperValu’s price-match guarantee. Wal-Mart’s program employed a set lower price (\$4 for 30-day generic prescriptions) automatically applied to any customer. By contrast, SuperValu’s discount prices could vacillate. Its discounts depended upon the pricing of local competitors, which could vary between SuperValu’s regional stores. SuperValu’s discounts also were customer-initiated in the first instance. The manual did not put SuperValu on notice that this type of discount program fell within the definition of U&C price—at least, not with the specificity required to be authoritative guidance. We hold that no authoritative guidance warned SuperValu away from its permissible interpretation of U&C price. The district court correctly granted summary judgment to SuperValu on the question of scienter.

### III. Conclusion

Our resolution of this case is controlled by *Safeco*. Today, we hold that *Safeco*’s standard both applies to the FCA’s scienter requirement and precludes liability under it, regardless of whether relators premise their case on reckless disregard or the other scienter terms. Because SuperValu had an objectively reasonable understanding of the regulatory definition of U&C price and no authoritative guidance placed it on notice of its error, the Relators have not shown that SuperValu acted knowingly. The district court’s judgment is

AFFIRMED.

HAMILTON, *Circuit Judge*, dissenting. We should reverse summary judgment for defendant SuperValu. The relators have come forward with evidence that SuperValu knowingly misled the government's agents about its "usual and customary" prices for a significant number and volume of prescription drug sales. For forty-four of the fifty top-selling drugs, SuperValu was charging the government prices *eight to fifteen times higher* than the prices it was actually charging a majority of the relevant customers. Binding circuit precedent holds that those price claims were false. SuperValu's defense is that it did not "know" its "usual and customary" price claims were false. When the False Claims Act is properly understood, however, genuine factual disputes over SuperValu's conduct and state of mind should preclude summary judgment.

This appeal presents a broad and important issue for the False Claims Act. The issue is whether the Act can reach businesses that submit false claims for government payment but claim there is some legal ambiguity that kept them from "knowing" for certain that their claims were false. Under the text and history of the Act, the answer should be yes.

The majority answers no. It thus creates a safe harbor for deliberate or reckless fraudsters whose lawyers can concoct a *post hoc* legal rationale that can pass a laugh test. The majority's new safe harbor even makes subjective bad faith "irrelevant" *in fraud cases*. Ante at 25. That undermines the 1986 amendments to the False Claims Act and turns the Act upside-down, losing touch with the statutory text and its history and links to the common law of fraud. I respectfully dissent.

Part I of this opinion explains the relators' claims and supporting evidence. Part II explains the better understanding of the False Claims Act's "knowledge" standard based on the

No. 20-2241

31

statutory text, the common law of fraud, and statutory history. Part III explains the majority's two fundamental errors in reading the statute. First, rather than focusing on the statutory text, history, and purpose of the False Claims Act itself, the majority reads far too much into *Safeco Insurance Co. v. Burr*, 551 U.S. 47 (2007), where the Supreme Court interpreted a different term under a different statute. Second, the majority turns into surplusage two-thirds of the False Claims Act's definition of "knowing" added in 1986.

#### I. *The Relators' Claims*

##### A. *The Relators' Evidence*

The majority explains helpfully the important role of "usual and customary" drug prices in Medicare and Medicaid. Congress has not allowed the government to do what private insurance companies do: use bargaining power to negotiate for lower drug prices. Instead, the government tries to take advantage of private competition in so-called "cash" sales of prescription drugs. See *United States ex rel. Garbe v. Kmart Corp.*, 824 F.3d 632, 644 (7th Cir. 2016). Those are sales to customers whose drug purchases are not covered by insurance. Under the statutes and regulations, SuperValu's "usual and customary" drug prices for those cash sales were caps on what the government would pay SuperValu for drugs provided to Medicare and Medicaid patients.

Starting in 2006, Walmart began offering cash sales of generic drug prescriptions for four dollars for a one-month supply and ten dollars for a three-month supply. SuperValu responded to Walmart's move with an aggressive, widely-advertised price-matching program. The result, giving relators the benefit of reasonable inferences from the evidence, was

dramatic reductions in the prices SuperValu charged most “cash” customers for many drugs for over a decade.

The applicable regulation describes the price cap as “Providers’ usual and customary charges to the general public.” 42 C.F.R. § 447.512(b)(2). Regulations also include this definition: “Usual and customary (U&C) price means the price that an out-of-network pharmacy or a physician’s office charges a customer who does not have any form of prescription drug coverage for a covered Part D drug.” 42 C.F.R. § 423.100.

In this appeal, SuperValu does not dispute that under now-binding circuit precedent, a discounted price can be the “usual and customary” price. See *Garbe*, 824 F.3d at 644–45. SuperValu also does not dispute that it pushed its price match as a matter of company policy and that it usually charged the four-dollar price for many drugs.

Relators offered evidence that SuperValu told the federal government for years that its “usual and customary” prices were much higher than those that it actually charged most cash customers for many drugs. The question here is whether plaintiffs have come forward with evidence to support a finding that SuperValu made these many false claims “knowingly.”

There is room for reasonable disagreement about *exactly* how to interpret “usual and customary” prices when a seller matches a competitor’s prices to keep a customer. That room for argument, says the majority, entitles SuperValu to summary judgment. As applied to these facts, though, it should be easy to find that SuperValu’s claims were false and that SuperValu knew they were false.

No. 20-2241

33

At one end of a spectrum, imagine a local mom-and-pop pharmacy that occasionally grants a few customers' informal requests for lower prices after some comparison shopping. At the other end, imagine a nationwide chain with a nationwide program advertising that the seller will match any competitor's lower prices. Then imagine that the seller tells its pharmacists and cashiers to offer the discounted prices to all customers paying cash for drugs (i.e., without insurance or government coverage). And then imagine that the seller makes a majority of its cash drug sales at the discounted rates, not at the *much* higher prices that it officially tells the government are "usual and customary." Relators' evidence here fits this end of the spectrum—SuperValu's price matches were available to any members of the general public, who were encouraged to ask for them.

Then consider relators' evidence about the results of this nationwide, decade-long program. Focus on SuperValu's sales of the fifty highest-volume drugs, where most of the relevant money is. For forty-four of those top fifty drugs, SuperValu was making a *majority* of its cash sales for less than its claimed "usual and customary" prices. For thirty of those drugs, SuperValu was making *more than eighty percent* of its cash sales for less than its claimed "usual and customary" prices.

Then consider that SuperValu was claiming that its "usual and customary" prices for those drugs were as much as *eight to fifteen times* the discounted prices it was actually charging *most of the time*. See Dew Rebuttal Report at 7–8. Given those facts, a reasonable jury could easily find both that SuperValu's claims for reimbursement based on its "usual and customary"



prices were false under any reasonable interpretation of the term and that SuperValu knew its claims were false.

B. *Ambiguity and Knowing Fraud*

Smart lawyers and judges can debate exactly how to define “usual and customary” under the infinite variety of situations we might hypothesize. But with respect, I do not see room for reasonable disagreement about whether claimed prices eight to fifteen times the actual cash prices that SuperValu charged most of the time were in any sense “usual and customary.” Without even reaching the direct evidence of knowledge, discussed below, a reasonable jury could infer that SuperValu’s decade-long practice of claiming higher reimbursement levels by disregarding the much higher prices it actually charged a majority of the time was a “knowing” fraud on the government. See 31 U.S.C. § 3729(a)(1). The disconnect between its representations (the higher prices were usual and customary) and reality (much lower prices were charged most of the time) is great enough that a jury could infer knowledge, as the term is defined in the False Claims Act, on that basis alone.

Then we come to the more direct evidence that SuperValu knew that what it was doing was fraudulent. The huge gaps between actual sale prices and claimed “usual and customary” prices did not escape notice by executives. Documents show that they paid close attention to the results of the price-matching program. That’s no surprise. The program responded to a major disruption in retail drug markets, with a big financial impact on cash sales. The executives also knew it had huge implications for the even higher volume of Medicare and Medicaid sales of those drugs. The executives estimated that the correct application of “usual and customary”

No. 20-2241

35

prices could cost SuperValu tens of millions of dollars per year.

Executives recognized that widespread price-matching could undermine what they euphemistically called the “integrity” of SuperValu’s “usual and customary” price claims for government reimbursement as price-matching became more than an “‘exception’ for customer services reasons.” And in the face of that concern, they chose what one called in an email the “stealthy” approach (scare-quotes in the SuperValu original) to ensure that word about this “exception” did not reach too many customers. The problem, of course, is that SuperValu’s price-matching was not only widespread but also advertised in all its stores. It knew that these practices were undermining the “integrity” of its certifications to the government, yet went forward anyway.

The False Claims Act requires proof that a defendant knowingly submitted false claims. It defines “knowing” of falsity to include acting “in deliberate ignorance of the truth or falsity” of the information submitted to the government. 31 U.S.C. § 3729(b)(1). A jury could reasonably find that SuperValu’s widespread adoption of price-matching on a scale far beyond an “exception” was at least a deliberate choice to remain ignorant about whether its ongoing claims based on supposedly “usual and customary” prices were false. A jury could also reasonably infer actual knowledge from the obvious and known effects of the gap between most actual sale prices under the nationwide price-matching and the claimed “usual and customary” prices. See *Farmer v. Brennan*, 511 U.S. 825, 836 (1994) (obvious risk of harm justifies inference of knowledge), cited in *Safeco Insurance*, 551 U.S. at 68.

SuperValu of course has arguments and evidence pointing toward its honesty and innocence. But we are reviewing a grant of summary judgment. The account set forth above is a reasonable view of the evidence in the light most favorable to the non-moving relators. A reasonable jury could find that SuperValu either actually knew or deliberately chose to keep itself in ignorance that it was submitting false, hugely inflated claims for reimbursement.

SuperValu does not dispute that it was selling forty-four of the top fifty drugs most of the time for much less than it claimed to the government were its “usual and customary” prices. Nor does it dispute that it was selling thirty of those drugs more than eighty percent of the time for much less than its claimed “usual and customary” prices. Instead, SuperValu points out that relators’ case is not limited to those high-volume drugs (“cherry-picked examples,” says SuperValu). Perhaps, but even if the relators tried to reach too far with other drugs, that would not mean their claims based on the “cherry-picked” drugs lack merit. The evidence of SuperValu’s actions and state of mind regarding those “cherry-picked” drugs can also shed light on others. After all, the price-match program covered lots of drugs over the decade it was in place.

Relators’ case here is factually complex because of time, geography, and the number of drugs involved. Their claims span a decade, during which SuperValu’s price-matching practices changed in arguably important ways. Their claims also span drug sales across a host of local and regional retail markets with different competitors and matched prices. And their claims cover hundreds of different drugs. That complexity should not distract us from the sound theory at the core of relators’ case. Where the price-matching program produced a

No. 20-2241

37

majority of actual sales at prices below the claimed “usual and customary” prices, the claimed prices could no longer be honestly deemed “usual and customary.”

## II. *Knowledge Under the False Claims Act*

SuperValu and the majority do not dispute this evidence or even the inferences that relators seek to draw from it. Instead, SuperValu and the majority say the evidence of SuperValu’s actual knowledge and intentions is “irrelevant.” Ante at 25. If that’s correct, this case creates a safe harbor for fraudsters who claim taxpayer funds in bad faith, but whose barely-straight-faced lawyers offer an innocent explanation for their conduct. The majority even says it is irrelevant whether SuperValu actually believed and/or relied upon the *post hoc* justifications offered in litigation. “[I]t is not enough that a defendant suspect or believe that its claim was false.” *Id.*, citing *United States ex rel. Purcell v. MWI Corp.*, 807 F.3d 281, 288 (D.C. Cir. 2015); ante at 20 (“A defendant might suspect, believe, or intend to file a false claim, but it cannot *know* that its claim is false if the requirements for that claim are unknown.”).

From 40,000 feet, that interpretation of the False Claims Act, or any cause of action for fraud, is extraordinary. It is a standard of knowledge we do not accept in any other areas of law, including criminal law. How many chief financial officers could say they did not “know” — not *really* — that the earnings reports were inflated, even if they suspected or believed they were? How many drug couriers could assert they did not really “know” that they were carrying drugs? Federal lawsuits and prosecutions are not seminars in such radical epistemological doubt. Federal courts routinely give “ostrich” instructions in response to such defenses, even in criminal cases:

“You may find that the defendant acted knowingly if you find beyond a reasonable doubt that he believed it was highly probable that [state fact as to which knowledge is in question, e.g., ‘drugs were in the suitcase,’ ‘the financial statement was false,'] and that he took deliberate action to avoid learning that fact.” Seventh Circuit Pattern Criminal Jury Instructions 4.10 (2020). We would never accept a defense theory based on such Cartesian doubt, and certainly not as a matter of law, in any other case requiring proof of knowledge of the key facts.

A. *Statutory Text and the Common Law*

Looking at the analysis more closely, the majority’s interpretation conflicts with the statutory text of the False Claims Act, its common-law foundations, and its history and purposes. Let’s start with the text of the Act. The key language imposes liability on a person who “knowingly presents, or causes to be presented, a false or fraudulent claim for payment or approval” or who “knowingly makes, uses, or causes to be made or used, a false record or statement material to a false or fraudulent claim.” 31 U.S.C. § 3729(a)(1).

The scienter standard is “knowingly,” and the Act then defines the term:

(b) Definitions. For purposes of this section—

(1) the terms “knowing” and “knowingly”—

(A) mean that a person, with respect to information—

(i) has actual knowledge of the information;

(ii) acts in deliberate ignorance of the truth or falsity of the information; or

(iii) acts in reckless disregard of the truth or falsity of the information; and

No. 20-2241

39

(B) require no proof of specific intent to defraud....

31 U.S.C. § 3729(b).

The three prongs of the statutory definition closely track the most authoritative summary of the common law's treatment of fraudulent scienter, used by the Supreme Court to interpret the False Claims Act. The Restatement (Second) of Torts § 526 (1977) also offers three prongs:

A misrepresentation is fraudulent if the maker

(a) knows or believes that the matter is not as he represents it to be,

(b) does not have the confidence in the accuracy of his representation that he states or implies, or

(c) knows that he does not have the basis for his representation that he states or implies.

The majority itself emphasizes that the Supreme Court has interpreted the False Claims Act consistently with the common law of fraud. Ante at 14, quoting *Universal Health Services, Inc. v. United States ex rel. Escobar*, 136 S. Ct. 1989, 1999 & n.2 (2016). That's certainly correct. *Escobar* relied on the Restatement (Second) of Torts, as did *Safeco* in interpreting the Fair Credit Reporting Act. 551 U.S. at 69.<sup>1</sup>

---

<sup>1</sup>The majority thinks § 526 is irrelevant in interpreting the False Claims Act's scienter standard, and that § 500 is a better guide because that's what *Safeco* cited for "reckless disregard." Ante at 16, citing *Safeco*, 551 U.S. at 69. That reasoning is circular. Section 500 addresses reckless disregard for the *safety* of another person. In other words, the majority is relying on the common law of reckless driving, not the common law of fraud. *Safeco* seems to have cited § 500 for lack of anything more pertinent to violations of the technical notice requirements of the Fair Credit

As Restatement § 526 shows, the common law definition of fraud makes subjective bad faith central to fraudulent scienter. Yet the majority concludes that bad faith is irrelevant ... in a fraud case! I would follow the Restatement, as echoed in the text of the False Claims Act itself. A reasonable jury could infer that SuperValu “knew” or “believed” that its higher prices were not its usual and customary prices, or, at the very least, did “not have the confidence in the accuracy” of its representations to the United States government that its certifications stated or implied. But see ante at 20 (“A defendant might suspect, believe, or intend to file a false claim, but it cannot *know* that its claim is false if the requirements for that claim are unknown.”).

---

Reporting Act. But § 526 appears in the Restatement Division on Misrepresentation, the Chapter on Misrepresentation and Nondisclosure Causing Pecuniary Loss, the Topic on Fraudulent Misrepresentation (Deceit), and Title A, Fraudulent Character of Misrepresentation. Section 526 is titled “Conditions Under Which Misrepresentation is Fraudulent (Scienter).” Each of its three prongs is phrased in terms of what the maker of the misrepresentation “*knows*.” Thus, for the common-law understanding of the False Claims Act’s definition of “knowing,” § 526 is right on target. (In *Escobar*, the Supreme Court relied on § 529, from the same topic on fraudulent misrepresentations. 136 S. Ct. at 1999.) And I confess to being baffled by the majority’s assertion: “We decline to graft aspects of common law fraudulent scienter into the FCA when Congress chose not to include such requirements.” Ante at 17. With respect, given the majority’s stated adherence to common-law understandings, what the maker of the false claims believes or suspects fits squarely into both the second and third prongs of 31 U.S.C. § 3729(b) and Restatement (Second) of Torts § 526. The common law of reckless driving (§ 500) does not provide the relevant scienter standard for a fraud case or a fraud statute.

No. 20-2241

41

B. *Origins of the Statutory Definition*

The majority fails to appreciate the importance of the False Claims Act's textual definitions of "knowingly" and their common-law roots. The majority instead focuses on the Supreme Court's interpretation of a different term in a different statute. That's a mistake. The False Claims Act's three-part definition of knowingly, with the disclaimer that specific intent to defraud is not required, did not come from nowhere. It was a clear instruction from Congress to courts to relax their restrictive interpretations of "knowing" under the Act.

Before 1986, the False Claims Act used the terms "knowing" and "knowingly" without elaboration. When Congress added the definitions in 1986, it acted in response to court decisions that were making it difficult to bring claims against dishonest claimants absent clear evidence of actual knowledge of the falsity of the claim. We should not ignore this history. The statutory text and history show Congress's clear intent to allow False Claims Act lawsuits to proceed against businesses that fail to do basic due diligence in response to warning signs that their government payments are ill-gotten.<sup>2</sup>

---

<sup>2</sup> The majority asserts it is an error to rely on statutory history to go "beyond the text" of the statute. Ante at 17. If the statutory text were clear as applied to this case, I might agree, but the majority obviously does not believe the statutory text of § 3729 is clear. Otherwise the majority would not need to rely on *Safeco*, addressing a different statute and different scienter standard. Since the text is not self-explanatory, it makes good sense to use reliable evidence to figure out what problem Congress was trying to solve. See also *Safeco* itself, where the Supreme Court said it was deciding as it did because there was "no indication that Congress had something different in mind." 551 U.S. at 69. The Court's comment invites



The amended three-pronged definition of “knowledge” in the False Claims Act was added in 1986 as part of a broader revision to the Act. As sponsor Senator Grassley explained, the government needed “lots of help” from Congress to identify fraudsters and bring them to justice. 132 Cong. Rec. S11243 (Aug. 11, 1986). Expanding the statute’s definition of “knowledge” to reach broader degrees of culpability was an important tool to reach that goal. *Id.*

The problem, as explained in the Senate Committee report, was that courts had applied too narrow a definition of “knowledge,” often requiring actual literal knowledge of a claim’s falsity or even specific intent to defraud to find liability under the Act. S. Rep. 99-345 at 7, citing *United States v. Aerodex*, 469 F.2d 1003 (5th Cir. 1972) (collecting cases). Given the “remedial” goals of the False Claims Act, the Committee sought to prevent courts from allowing unscrupulous claimants, acting in bad faith, to evade liability through legal technicalities about the definition of “knowledge.” See S. Rep. 99-345 at 7, 21.

The result of these earlier court decisions had been predictable: unscrupulous claimants could structure claim-processing procedures so that false claims could be filed without the relevant decision-makers truly “knowing” of the fraud. *Id.* at 7. Even if hints of possible wrongdoing surfaced, decision-makers could insulate themselves from liability by ignoring problems that even a cursory investigation would have uncovered. *Id.*

---

reliance on statutory history to answer these questions where the text is not entirely clear.

No. 20-2241

43

In explaining the statutory text, the House Judiciary Committee noted the problems from the lack of a definition of “knowledge” and reported:

By adopting this [three-pronged] definition of knowledge, the committee intends not only to cover those individuals who file a claim with actual knowledge that the information is false, but also to confer liability upon those individuals who deliberately ignore or act in reckless disregard of the falsity of the information contained in the claim. *It is intended that persons who ignore “red flags” that the information may not be accurate or those persons who deliberately choose to remain ignorant of the process through which their company handles a claim should be held liable under the Act.* This definition, therefore, enables the Government not only to effectively prosecute those persons who have actual knowledge, but also those who play “ostrich.”

H. Rep. 99-660 at 21 (emphasis added).

The Senate Committee also focused on proverbial “ostriches” who stick their heads in the sand instead of verifying that they are not cheating taxpayers. S. Rep. 99-345 at 7, 15, 21. These ostriches need not have “conscious culpability” of wrongdoing: people who submit claims that they have “reason to know” are potentially false run the risk of violating the Act if they “fail[] to inquire” as to the falsity of the claims. 132 Cong. Rec. S11243–44 (Aug. 11, 1986; statement of Senator Grassley).

The Committee reports explained that the added definition was aimed at claimants who acted in bad faith by failing to investigate potential problems: “those doing business with the Government have an obligation to make a limited inquiry to ensure the claims they submit are accurate.” S. Rep. 99-345 at 7. Congress chose statutory language that could have been custom-tailored for SuperValu’s approach in this case. SuperValu knew that the “integrity” of its “usual and customary” prices would be suspect if price-matching were not the “exception” but the rule, yet it kept submitting those claims through a nationwide price-matching campaign anyway, netting tens of millions of dollars of public funds annually.

This is the same standard that the Eleventh Circuit adopted in *United States ex rel. Phalp v. Lincare Holdings, Inc.*, 857 F.3d 1148 (11th Cir. 2017), another case involving arguable regulatory ambiguity. After considering the statutory text and legislative history, the court concluded that “scienter is not determined by the ambiguity of a regulation, and can exist even if a defendant’s interpretation is reasonable.” *Id.* at 1155, citing the Senate Committee Report indicating Congressional intent to require claimants to engage in “limited inquiry.” *Phalp* also squarely rejected the majority’s position here: “The district court’s conclusion that a finding of scienter can be precluded by a defendant’s identification of a reasonable interpretation of an ambiguous regulation that would have permitted its conduct is erroneous.” *Id.* (*Phalp*’s treatment of this issue refutes the majority’s attempt to explain it away. See ante at 15.) The *Phalp* court’s interpretations of the Act’s scienter definition should be obviously correct.

In fact, before the *Safeco* progeny cited by the majority, our colleagues in other circuits followed the amended text of the

No. 20-2241

45

False Claims Act and common sense: a claimant could be liable under the Act notwithstanding a purported regulatory ambiguity if the defendant deliberately ignored the falsity of the claim or otherwise acted in bad faith. *United States v. Science Applications International Corp.*, 626 F.3d 1257, 1272–73 (D.C. Cir. 2010) (affirming verdict for United States; jury could infer that defendant knew its claims were false notwithstanding “regulatory divide” in how to interpret a regulation); *United States ex rel. Oliver v. Parsons Co.*, 195 F.3d 457, 464 (9th Cir. 1999) (reversing summary judgment: “In short, [defendant’s] petition arguing that the sky will fall upon government contractors if they are precluded from relying on a ‘reasonable interpretation’ is not only unsupported by case law, it is also ungrounded in reality.”); see also *Minnesota Ass’n of Nurse Anesthetists v. Allina Health System Corp.*, 276 F.3d 1032, 1053 (8th Cir. 2002) (citing *Parsons* for the proposition that “any possible ambiguity of the regulations is water under the bridge” where contractor’s misinterpretation is “knowing”).<sup>3</sup>

In this case, the relators’ evidence shows that SuperValu knew it was claiming high “usual and customary” prices that it was charging less than half the time, often less than one fifth

---

<sup>3</sup> We took a similar approach in *United States ex rel. Sheet Metal Workers Int’l Ass’n, Local Union 20 v. Horning Investments, LLC*, 828 F.3d 587 (7th Cir. 2016). The defendant argued that it relied on advice of professional experts in determining that its claims were not false. We rejected that argument on grounds inconsistent with the majority approach here. Rather than treat a professional’s ability to find ambiguity as a defense in itself, we applied a much more demanding five-part test that required proof of timely, good-faith, and full disclosure to competent experts. *Id.* at 594–95. We ultimately affirmed summary judgment for the defendants, but on a different ground, that the relator simply did not have evidence that defendants were on notice that their claims were false. *Id.* at 595.

of the time. SuperValu knew that its practices raised questions about the “integrity” of its “usual and customary” prices but nonetheless ignored those concerns. The False Claims Act’s statutory definition of “knowing” reaches those who know their claims are false or who act in deliberate ignorance of whether their claims were true or false. We should reverse summary judgment for SuperValu.

### III. *The Majority’s Safeco Tangent*

Rather than focusing on the language of the False Claims Act itself, and its origins in the common law of fraud and responses to crabbed judicial interpretations, the majority opinion takes a very different approach. It borrows the Supreme Court’s treatment of a different term, “willfully,” under a different statute, the Fair Credit Reporting Act, in *Safeco Insurance Co. v. Burr*, 551 U.S. 47 (2007). The majority adopts *Safeco’s* treatment of reckless disregard for law as a branch of “willful” misconduct. The majority then goes even further and concludes that relators must meet that standard for reckless disregard for any False Claims Act case, even if they rely on the actual-knowledge or deliberate-ignorance prongs of the Act’s definition of knowing.

The majority makes two fundamental mistakes. First, the reliance on *Safeco* to understand “reckless disregard” is neither necessary nor fitting for the False Claims Act. The Act draws on a different branch of the common law (of fraud, not reckless driving), and the history of the statutory amendments shows that Congress thought it was enacting a standard quite different from the majority’s. Second, by saying relators must satisfy the *Safeco* reckless-disregard standard in any case, the majority effectively nullifies two-thirds of the statutory definition of “knowing.” To explain:

No. 20-2241

47

The question in *Safeco* was whether an insurer's decision about an initial premium rate for an insured could qualify as an "adverse action" based on a credit report that could require notice to the consumer in question. The Supreme Court ultimately held that it could but also held that Safeco had not "willfully" violated that Act because the statute and regulation were not clear as applied to initial premium decisions, so that Safeco had not acted willfully.

The Fair Credit Reporting Act does not define "willfully," which the Court described as a "word of many meanings whose construction is often dependent on the context in which it appears." 551 U.S. at 57, quoting *Bryan v. United States*, 524 U.S. 184, 191 (1998). Without more specific guidance for interpreting the term in that act, the *Safeco* Court had little choice but to construct a working definition from multiple sources. The Court focused on civil law, noting that in several civil contexts, willful violations of statutes could be shown by recklessness, which was consistent with common-law use of the term. *Id.* Then, because there was "no indication that Congress had something different in mind," and because the term "recklessness" is not "self-defining," the Court announced an application of that scienter standard to the Fair Credit Reporting Act. *Id.* at 57–58, 68–69.

The Court then drew on common-law definitions of "recklessness" that apply to actions putting others in physical danger. The Court described recklessness as action entailing "an unjustifiably high risk of harm that is either known or so obvious that it should be known," *id.* at 68, quoting *Farmer v. Brennan*, 511 U.S. 825, 836 (1994), and conduct involving "unreasonable risk of physical harm ... substantially greater than that which is necessary to make his conduct negligent. *Id.* at

69, quoting Restatement (Second) of Torts § 500 (also regarding putting another person in physical danger). The Court summarized its view for the Fair Credit Reporting Act:

*There being no indication that Congress had something different in mind, we have no reason to deviate from the common law understanding in applying the statute. Thus, a company subject to FCRA does not act in reckless disregard of it unless the action is not only a violation under a reasonable reading of the statute's terms, but shows that the company ran a risk of violating the law substantially greater than the risk associated with a reading that was merely careless.*

551 U.S. at 69 (emphasis added; citation omitted). Along the way, the Court added footnote 20, saying that evidence of subjective bad faith would not be relevant to the definition of willfulness in 15 U.S.C. § 1681n(a) where a company followed an objectively reasonable interpretation of the Fair Credit Reporting Act.

The majority here and four other circuits have borrowed this reasoning from *Safeco* and grafted it onto the False Claims Act. Two of those circuits did so in non-precedential decisions. The two precedential decisions are *United States ex rel. Purcell v. MWI Corp.*, 807 F.3d 281 (D.C. Cir. 2015), and *United States ex rel. Donegan v. Anesthesia Associates of Kansas City*, 833 F.3d 874 (8th Cir. 2016). The Eleventh Circuit reached a different conclusion in *Phalp*, 857 F.3d 1148, discussed above. (The *Phalp* opinion did not discuss *Safeco* or *Purcell*, but both cases were briefed extensively, including by the United States in an amicus brief arguing that *Safeco* provided no meaningful guidance for False Claims Act cases. There is no doubt that

No. 20-2241

49

the Eleventh Circuit rejected *Purcell's* borrowing of *Safeco*. It did not cite *Safeco* because, for reasons explained here, *Safeco* simply is not needed to interpret the scienter requirement of the False Claims Act.)

In the absence of better guidance for the False Claims Act and common law, reliance on *Safeco* might be understandable, if a bit of a stretch. The majority here errs, however, by overlooking *Safeco's* directive: first check to see if “Congress had something different in mind.” 551 U.S. at 57, 69. With the False Claims Act, we *do* have meaningful guidance from the statutory text, the common law, and legislative history, as discussed above.

If the majority limited its reliance on *Safeco* to the reckless-disregard prong of the False Claims Act's definition of knowing, its mistake would be more understandable. It's the majority opinion's next move that is more extraordinary and much more damaging. The majority concludes that a relator under the False Claims Act must satisfy the *Safeco* definition of reckless disregard—show that no reasonable understanding of law could justify the defendant's action, or show that the defendant disregarded “authoritative guidance” —*in every case*, even those relying on the actual-knowledge and deliberate-ignorance prongs of the definition of “knowingly.” As a result, the majority holds in effect that those two-thirds of the statutory definition add zero meaning to the statute.

The majority's major premise is that “reckless disregard” is the broadest of the three prongs. Its minor premise is that any case of “actual knowledge” or “deliberate ignorance” would *always* fall within “reckless disregard,” *as that term was defined in Safeco*. That too-simple heuristic may be useful in



some easy cases, but its application here is inconsistent with how courts should read statutes.

The key logical error lies in the minor premise, that any case of actual knowledge or deliberate ignorance would necessarily also be covered by *Safeco*-reckless disregard. There is no basis for that assumption, which leads away from the common law of fraud, where subjective bad faith is central.

Consider a hypothetical close to this case. A government contractor submits claims believing, subjectively, that the claims are probably false. The agency has not yet provided what *Safeco* would call “authoritative guidance,” but the contractor reads the controlling regulation (correctly) to preclude its claim. Still, it decides to stay quiet, hoping it will not get caught, or at least not too quickly. In that situation, judges and jurors can say that claims were fraudulent and the contractor knew it, even if a creative lawyer can later make a non-frivolous legal argument for its innocence. Likewise, the contractor acted with fraudulent intent because it “believed” the claims were false and submitted claims in which it did not have the “confidence” it claimed. See 31 U.S.C. § 3729(b); Restatement (Second) of Torts § 526.

This bad-faith “catch us if you can” approach to public funds is exactly what Congress thought it was outlawing when it decided in 1986 that it needed to define “knowledge” more specifically for the False Claims Act, including to reach deliberate ignorance of falsity. Recall also that under the majority’s approach, there is no need for a defendant to show that it actually “followed” any “objectively reasonable” interpretation of the law that would supposedly save the claims from being false. See ante at 25.

No. 20-2241

51

The majority's logic thus takes the False Claims Act in a direction 180 degrees away from common-law fraud. It makes subjective bad faith, including deliberate ignorance, "irrelevant." *Id.* That's contrary to both the actual-knowledge and deliberate-ignorance prongs of the Act's textual definition. It loses sight of the fact that the Act applies to "fraudulent" conduct. And it's also contrary to the common-law scienter standard in the Restatement (Second) of Torts, which is satisfied if the defendant "knows or believes that the matter is not as he represents it to be," or if he "does not have the confidence in the accuracy of his representation that he states or implies...." § 526 (emphasis added).

The majority rests heavily on *Safeco's* footnote 20 to support its new safe harbor where subjective state of mind is irrelevant. See ante at 19. With respect, the majority reads far too much into that footnote, which by its own terms is limited to "determining whether a company acted knowingly or recklessly for purposes of § 1681n(a)." By the majority's reading, that footnote in an opinion on credit reporting requirements, which borrowed from the common law of reckless driving, upended the common law of *fraud*, one of the paradigmatic intentional torts, where state of mind is critical. The *Safeco* Court gave no sign that its footnote intended to reach beyond § 1681n(a) or that it was creating a new element for fraud claims—the absence of any plausible reading that would render the false statement true. The majority's too-broad reading leads it to depart from the text of the False Claims Act and loses sight of Congress's clear intent.

In fact, the Supreme Court itself has warned against reading *Safeco's* footnote 20 so broadly. It did so in *Halo Electronics, Inc. v. Pulse Electronics, Inc.*, 136 S. Ct. 1923, 1933 n.\* (2016). The

Court declined to extend the *Safeco* definition of “willfully” to treble-damage awards for patent infringement under 35 U.S.C. § 284. Subjectively bad-faith infringement, focused on the defendant’s state of mind when it acted, had long been an independent basis for enhanced patent damages. 136 S. Ct. at 1933 & n.\*. As the majority points out here, ante at 17–18, in *Halo Electronics*, differences in the two statutes produced different scienter standards. Exactly the same reasoning should apply here. The differences between the texts and histories of the Fair Credit Reporting Act and False Claims Act should lead us to decline to extend the *Safeco* standard and its footnote 20 to the False Claims Act.

Returning to False Claims Act cases, consider, for example, *United States ex rel. Prather v. Brookdale Senior Living Communities, Inc.*, 892 F.3d 822, 837–38 (6th Cir. 2018), where the Sixth Circuit reversed dismissal of a relator’s complaint. The complaint alleged that the relator and other nurses had “concerns about the defendants’ compliance with Medicare regulations, but were told to ignore any problems.” When relator raised issues about regulatory compliance, executives told her on multiple occasions that “[w]e can just argue in our favor if we get audited’ as a solution to any compliance issues.” The Sixth Circuit reasoned that the allegations about notice of compliance problems imposed an obligation on the defendants to inquire whether they were actually in compliance with regulations. The Sixth Circuit concluded the allegations supported “knowledge” under both the deliberate-ignorance and reckless-disregard prongs of the definition. *Id.* at 838. Yet under the majority’s approach here, that case would have been dismissed so long as an attorney could later offer a barely-plausible theory of innocence, even though the defendant ignored repeated and correct warnings that it was violating the

No. 20-2241

53

regulations. Worse yet, the majority here would have dismissed the case even if the supervisors had admitted that they *knew* their submissions were non-compliant.

The majority's bottom line—that only objectively reckless disregard matters, and subjective bad faith does not—also violates one of the most common tools of statutory interpretation. It renders the actual-knowledge and deliberate-ignorance prongs of the statutory definition utterly superfluous. See *City of Chicago v. Fulton*, 141 S. Ct. 585, 591 (2021) (“The canon against surplusage is strongest when an interpretation would render superfluous another part of the same statutory scheme.”), quoting *Yates v. United States*, 574 U.S. 528, 543 (2015) (plurality); *National Ass’n of Mfrs. v. Dep’t of Defense*, 138 S. Ct. 617, 632 (2018), quoting *Reiter v. Sonotone Corp.*, 442 U.S. 330, 339 (1979); *In re Southwest Airlines Voucher Litig.*, 799 F.3d 701, 710 (7th Cir. 2015); Antonin Scalia & Bryan Garner, *Reading Law: The Interpretation of Legal Texts* 174 (2012) (“The surplusage canon holds that it is no more the court’s function to revise by subtraction than by addition.”).

The canon against surplusage is not absolute, of course. Sometimes drafters of legal documents may “intentionally err on the side of redundancy to ‘capture the universe.’” *Sterling Nat’l Bank v. Block*, 984 F.3d 1210, 1218 (7th Cir. 2021), quoting Abbe R. Gluck & Lisa Schultz Bressman, *Statutory Interpretation from the Inside—an Empirical Study of Congressional Drafting, Delegation, and the Canons: Part I*, 65 *Stan. L. Rev.* 901, 934 (2013); accord, e.g., *Rimini Street, Inc. v. Oracle USA, Inc.*, 139 S. Ct. 873, 881 (2019); *White v. United Airlines, Inc.*, 987 F.3d 616, 622 (7th Cir. 2021).

The False Claims Act definition of “knowingly” is about as strong a case for the canon against surplusage as one is

likely to find. The three prongs mirror three distinct common-law prongs for fraudulent scienter. Congress adopted them to give courts clearer guidance because Congress was disappointed with courts' interpretations of the undefined "knowing." Congressional leaders on the subject, such as Senator Grassley and Representative Berman, were concerned that courts would continue to misinterpret the statute. They explained exactly how the definition of "knowing" should be applied, as did the respective committees. The three prongs may overlap in many cases, but the adoption of the three distinct prongs in the same paragraph of the statutory text was unmistakably an effort to be both thorough and broad. Congress said as clearly as it could that the False Claims Act should reach just this kind of case.

I close with two final observations about the majority's misguided holding. First, even under the *Safeco* standard, a reasonable jury could find that SuperValu's more extreme conduct here was not reasonable. There is simply no reasonable definition of "usual and customary" that means "something we do less than half the time and that we instruct our employees not to do." Defining "usual and customary" to mean the opposite of what those two words actually mean is simply not reasonable.

Second, the majority's approach actually leaves the False Claims Act definition of knowledge *narrower* than when the 1986 amendment was passed. Consider, for example, *United States v. Mead*, 426 F.2d 118, 122–23 (9th Cir. 1970), which Representative Fish singled out as applying a too-narrow definition of knowledge. 132 Cong. Rec. H6480 (Sept. 9, 1986); see also *Aerodex*, 469 F.2d at 1007, cited negatively in S. Rep. 99-345 (collecting *Mead* as an example of then-operative

No. 20-2241

55

knowledge standard). In *Mead*, the court explained that where regulatory language is uncertain and even the district court misinterpreted the regulations, scienter is still a question of fact. If the government had shown that Mead knew his regulatory interpretation was wrong or had fraudulent intent, he would still be liable under the Act. See also *United States v. Ueber*, 299 F.2d 310, 314 (6th Cir. 1962), cited negatively in S. Rep. 99-345 (where contract distinguished between “direct” and “indirect” labor costs, falsity of claims for “direct” labor costs and defendant’s knowledge of their falsity are questions of fact for trial; remanding for further fact-finding). Whatever “reckless disregard” means, we should not use it to *narrow* the definition of knowledge that Congress thought it was expanding.

To sum up, relators have come forward with substantial evidence of knowing fraud, as SuperValu claimed reimbursement at supposedly “usual and customary” prices for drugs that were as much as eight to fifteen times higher than the prices it was actually charging the general public a majority of the time. The evidence supports a reasonable inference of actual knowledge or at least deliberate ignorance or reckless disregard for whether its reimbursement claims were false. We should reverse summary judgment and remand for trial on relators’ claims. With respect, I believe that both Congress and the Supreme Court will be surprised by this decision and the others extending *Safeco* to the False Claims Act. If the False Claims Act is to remain effective in discouraging and remedying fraudulent raids on taxpayer dollars, Congress or the Supreme Court or both will need to respond to this line of cases.

# **APPENDIX B**

United States Court of Appeals  
For the Seventh Circuit  
Chicago, Illinois 60604

December 3, 2021

**Before**

ILANA DIAMOND ROVNER, *Circuit Judge*

DAVID F. HAMILTON, *Circuit Judge*

AMY J. ST. EVE, *Circuit Judge*

No. 20-2241

UNITED STATES OF AMERICA ex rel.  
TRACY SCHUTTE, *et al.*,  
*Relators-Appellants,*

*v.*

SUPERVALU INC., *et al.*,  
*Defendants-Appellees.*

Appeal from the United States District  
Court for the Central District of Illinois.

No. 11-cv-3290

Richard Mills,  
*Judge.*

**ORDER**

On consideration of the petition for rehearing and petition for rehearing *en banc*, no judge<sup>1</sup> in regular active service has requested a vote on the petition for rehearing *en banc* and the judges on the original panel have voted to deny rehearing. It is, therefore, **ORDERED** that the petition for rehearing and petition for rehearing *en banc* is **DENIED**.

---

<sup>1</sup> Judge Candace Jackson-Akiwumi did not participate in the consideration of this matter.